Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Defective opsonization in multiple myeloma.

B D Cheson, R R Plass, G Rothstein

    Blood
    |April 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Multiple myeloma patients exhibit reduced opsonization, a key immune function. This study reveals a significant defect in their serum

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

    Annals of oncology : official journal of the European Society for Medical Oncology·2018
    Same author

    A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia.

    Leukemia & lymphoma·2016
    Same author

    Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

    Leukemia·2015
    Same author

    Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.

    Blood cancer journal·2014
    Same journal

    Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

    Blood·2026
    Same journal

    Identifying steroid-refractory aGVHD before it happens.

    Blood·2026
    Same journal

    ELISA-negative HIT: antibody recognition and relevance.

    Blood·2026
    Same journal

    EBV and immunodeficiency: the odd couple drawn to the brain.

    Blood·2026
    Same journal

    A bone to pick with ferric carboxymaltose.

    Blood·2026
    Same journal

    A step toward streamlining HIT diagnosis.

    Blood·2026
    See all related articles

    Area of Science:

    • Immunology
    • Hematology
    • Clinical Medicine

    Background:

    • Multiple myeloma (MM) patients are unusually susceptible to infections.
    • MM is associated with decreased production of normal serum proteins.
    • The role of opsonins in MM-related immune dysfunction is unclear.

    Purpose of the Study:

    • To investigate impaired opsonin production in multiple myeloma patients.
    • To evaluate the opsonic activity of serum from MM patients.

    Main Methods:

    • Neutrophil chemiluminescence assay of opsonization was employed.
    • Serum from 18 MM patients and 18 healthy controls was analyzed.
    • Mixture experiments with normal and heat-inactivated serum were performed.

    Related Experiment Videos

    Main Results:

    • MM patient serum showed 50% less opsonic activity compared to controls (p < 0.001).
    • Normal serum restored opsonic activity, indicating a deficiency, not an inhibitor.
    • Low C3 levels were observed in some patients, correlating with greater opsonic defects (p < 0.02).

    Conclusions:

    • MM serum exhibits both heat-stable and heat-labile opsonic deficiencies.
    • Defective host resistance in MM may be multifactoral, including opsonic abnormalities.
    • The direct clinical significance of these opsonic defects requires further clarification.